Current HIV clinical trial design issues

Article Abstract:

Effective drug combinations are likely to reduce the viral load in HIV infection, which is considered a more appropriate marker of disease progression than clinical end points. Since drug testing involves patients at increasingly earlier stages of infection, the clinical outcome is changing from hard criteria, such as advanced AIDS, to the effect of the drug on the virus itself. Antiviral effectiveness also needs to be established among patients without advanced HIV infection. Regulatory drug licensing could be linked to the therapeutic evidence of drugs reducing viral load for extended periods of time. Recent insights into the effectiveness of triple-drug combination therapy should prompt further investigations on drugs that suppress viral replication, preventing further deterioration of the immune function.

Standards, Drugs, Testing, Clinical trials, Drug therapy, Combination, Combination drug therapy

---

Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection

Article Abstract:

Blood levels of soluble tumor necrosis factor receptors p55 and p75 probably have little value as mortality predictors during zidovudine treatment of HIV symptomatic patients. Tumor necrosis factors are natural or synthetic proteins with anticancer effects which fight off toxic substances. The p55 and p75 receptors have been effective markers for HIV progression in patients without symptoms. During zidovudine treatment, the T-cell counts of 40 symptomatic HIV patients in zidovudine treatment statistically compared with blood levels of p55 and p75 showed no predictive markers for survival.

Physiological aspects, Development and progression, Tumor necrosis factor, Zidovudine

---

Inhibition of HIV replication by sense and antisense Rev response elements in HIV-based retroviral vectors

Article Abstract:

An antisense version of an HIV RNA sequence might be a promising treatment for HIV infection. The RNA sequence is called the Rev response element, or RRE, because the viral Rev protein binds to it. Binding of Rev to RRE is crucial for HIV replication. Researchers showed that both sense and antisense versions of RRE inhibited viral reproduction in an HIV-infected cell line.

Similar abstracts:

• Abstracts: Multicenter clinical trial of ibuprofen and acetaminophen in the treatment of postoperative dental pain. Antipyretic efficacy of ibuprofen and acetaminophen in children with febrile seizures
• Abstracts: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary
• Abstracts: Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.